Depression, Parkinson Disease
Conditions
Keywords
Parkinson Disease, Parkinsonism, Depression, OnabotulinumtoxinA, BOTOX
Brief summary
This study evaluates the efficacy of onabotulinumtoxinA (BOTOX®) in the treatment of depression associated with Idiopathic Parkinson Disease in adults. As a Randomized Controlled Trial, half of the participants will receive onabotulinumtoxinA injections and half will receive a placebo saline solution.
Detailed description
Depression is a common, but treatable, comorbid condition often seen in persons with Idiopathic Parkinson Disease (iPD). Depression in Parkinson Disease may be hard to treat as patients with iPD may be sensitive to side effect of medication. As a result, other treatments which have better side effects profiles than antidepressants may be equivalent (or better) options. OnabotulinumtoxinA is a purified formulation of botulinum toxin serotype A which is widely utilized for neurological (and cosmetic) purposes in medicine. OnabotulinumtoxinA has preliminary studies showing it may be beneficial for the treatment of Major Depressive Disorder when given in isolated injections to facial muscles (corrugator and procerus). When given in low doses, onabotulinumtoxinA is thought to have minimal side effects. The investigators propose that a single treatment onabotulinumtoxinA may improve symptoms of depression in persons with Parkinson Disease over three months compared to placebo. The investigators plan to use both subjective and objective evaluations of depression symptoms and regular physical exams to ensure physical (motor) symptoms of Parkinson Disease do not worsen.
Interventions
BIOLOGICALOnabotulinumtoxinA
OnabotulinumtoxinA (29 units for women; 40 units for men) diluted with 0.9% sodium chloride (saline) solution to 40 units per milliliter (mL) (0.725 mL for women, 1 mL for men)
BIOLOGICALControl
0.9% sodium chloride solution (saline) solution injections (0.725mL for women, 1mL for men)
Sponsors
Johns Hopkins University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 95 Years
Healthy volunteers
No
Inclusion criteria
* Written informed consent is obtained in the English language; * They are a 18 to 95 years old; * They meet United Kingdom Brain Bank Criteria for probable idiopathic Parkinson disease; * They meet Diagnostic and Statistical Manual (DSM)-IV criteria for major depressive disorder (MDD) as diagnosed by the M.I.N.I. at screening; * They are judged by the investigator to have the capacity to understand the nature of the study; * They are willing to comply with all the requirements of the study; * They are considered by the investigator to be likely to adhere to the protocol.
Exclusion criteria
* They have been treated with onabotulinumtoxinA injected into the facial muscles for any reason in the 3 months prior to screening; * They have Bipolar Disorder, Post-Traumatic Stress Disorder, a Psychotic Disorder or any other non-unipolar depressive disorder as a principal diagnosis in the 6 months prior to screening; * They endorse active suicidal ideation at enrollment or during any study visit, or have attempted suicide in the six months prior to screening; * They have a history of substance abuse or dependence in the 2 months prior to screening; * They test positive for illicit drugs on urine screen, and this has not been adequately explained to the satisfaction of the investigator * They are considered to be at significant risk of committing homicide; * They have an unstable medical condition; * Women of childbearing potential who are pregnant or are considering becoming pregnant during the length of the study; * There has been a change in their PD medication or psychotherapy treatment regimen in the 30 days preceding screening; * They are regarded, for any reason, by the principal investigator as being an unsuitable candidate for the protocol.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Hamilton Rating Scale for Depression (HDRS) | Baseline and two visits over three months (weeks 6 and 12) | Improvement on a clinician-rated objective scale for depression as assessed over two weeks (6 weeks and 12 weeks after treatment) |
| Clinical Global Impression - Improvement (CGI-I) | Baseline and two visits over three months (weeks 6 and 12) | Improvement on a measure of global change from screening to study discontinuation |
| Clinical Global Impression - Severity (CGI-S) | Baseline and two visits over three months (weeks 6 and 12) | Improvement on measure of global illness severity from screening to study discontinuation |
| Beck Depression Inventory II | Baseline and two visits over three months (weeks 6 and 12) | Improvement on a participant-rated subjective scale for depression as assessed over two visits |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Clinical Severity Score for Glabellar Frown Lines | Baseline and two visits over three months (weeks 6 and 12) | Assessment of change in participant frowning before and after onabotulinumtoxinA injections and relationship with depressive symptoms |
Countries
United States
Outcome results
None listed